| 000 | 01457 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517015243.0 | ||
| 264 | 0 | _c20150625 | |
| 008 | 201506s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1002/cpt.86 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSimon, R | |
| 245 | 0 | 0 |
_aThe role of nonrandomized trials in the evaluation of oncology drugs. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cMay 2015 |
||
| 300 |
_a502-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xmethods |
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 | _aEndpoint Determination |
| 650 | 0 | 4 |
_aEvidence-Based Medicine _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMedical Oncology _xmethods |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aResearch Design _xstandards |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBlumenthal, G M | |
| 700 | 1 | _aRothenberg, M L | |
| 700 | 1 | _aSommer, J | |
| 700 | 1 | _aRoberts, S A | |
| 700 | 1 | _aArmstrong, D K | |
| 700 | 1 | _aLaVange, L M | |
| 700 | 1 | _aPazdur, R | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 97 _gno. 5 _gp. 502-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpt.86 _zAvailable from publisher's website |
| 999 |
_c24618317 _d24618317 |
||